John F. Kurland

机构：AstraZeneca (Netherlands), AstraZeneca (Poland), AstraZeneca (Spain) · ORCID：0000-0003-0863-2486

发表论文 109 篇 · 总被引 6742 次 · h-index 25

代表论文

• Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer (2025 · New England Journal of Medicine · 被引 274)
• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 270)
• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC (2025 · Journal of Hepatology · 被引 141)
• Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers (2025 · Journal for ImmunoTherapy of Cancer · 被引 7)
• T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC). (2024 · Journal of Clinical Oncology · 被引 2)
• Data from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma (2026 · 被引 1)